Abstract:
This invention provides a Fe 3 O 4 /TiO 2  composite nano-particle, its preparation and application in the magnetic resonance imaging (MRI) contrast agent, wherein the preparation of Fe 3 O 4 /TiO 2  composite nano-particles has the followings steps: trivalent iron compounds and bivalent iron compounds are dissolved into a reducing acid water solution, and then added with tetravalent titanium salt solution to obtain the Fe 3 O 4 /TiO 2  composite nano-particle sol. The Fe 3 O 4 /TiO 2  composite nano-particles prepared by the method in the invention have the properties of superparamagnetism and photocatalytic activity and can be applied to MRI contrast agents.

Description:
FIELD OF THE INVENTION  
       [0001]    The present invention relates to nano-particles, preparation and application thereof, especially Fe 3 O 4 /TiO 2  composite nano-particles, their preparation and application in Magnetic Resonance Imaging contrast agents. 
       BACKGROUND OF THE INVENTION 
       [0002]    At present, Magnetic Resonance Imaging (MRI) is one of the most important imaging technologies in clinic diagnosis of any part of human body in modern medicine because of its advantages of safety, high imaging resolution, less artifacts and abundant information. In medical diagnosis, the MRI sensitivity bears a very important relationship with the contrast agent materials used. The material that can be used as an MRI contrast agent includes nano-materials such as super paramagnetic oxide nano-particles and gadolinium containing coordination compounds. Due to non-toxicity and relatively strong magnetic characteristics, the superparamagnetic iron oxide (Fe 3 O 4 ) nano-particles are widely researched in the field of MRI T 2  and/or T 2 * contrast agent materials, compared to the frequently used T 1  contrast agent that is made of gadolinium coordination compounds. At present, the Fe 3 O 4  nano-materials are often prepared by the coprecipitation method: ferric salt is firstly dissolved in a solvent and then vigorously stirred to obtain Fe 3 O 4  nano-particles under basic conditions; and the products is naturally precipitated or magnetically separated to obtain Fe 3 O 4  nano-particles. In this method, both inorganic/organic ferric salt and inorganic/organic solvents are used. Although Fe 3 O 4  nano-materials can be made according to this method, the particle diameter is relatively large. In addition, the Fe 3 O 4  nano-particles prepared by this method have poor water-soluability and poor bio-compatability, which limit their applications in biomedicine field, especially application in MRI contrast agents. Therefore, the problems of toxicity, solubility and biocompatibility shall be solved before the magnetic nano-materials are applied in MRI contrast agents and medical therapy. 
         [0003]    In addition, individual Fe 3 O 4  nano-particles only have T 2  and/or T 2 * weighted signals with common signal intensity contrast in MRI tests. T 1  weighted signals only occur if the particle size is very small. Moreover, superparamagnetic Fe 3 O 4  nano-particle contrast agent is usually applied to medical imaging diagnosis, but very difficult to be combined with biological molecules or drug molecules in medical treatment. 
         [0004]    Nano titanium dioxide (TiO 2 ) is an important photocatalytic material, widely used in the fields of chemical catalysis, energy and photodegradation of environmental pollutants. Using the photocatalytic activity of TiO 2  or linking TiO 2  nano-particles to biological molecules or drug molecules to form nano-copolymers, one can use the TiO 2  nano-materials in disease treatment. 
         [0005]    Therefore, application of above said environmental-friendly nontoxic Fe 3 O 4 /TiO 2  composite nano-particles with good solubility and biocompatibility to the MRI contrast agent field helps develop a high-resolution and informative MRI contrast agent having T 1 , T 2  and/or T 2 * weighted signals. The Fe 3 O 4 /TiO 2  composite nano-particles can have medical therapeutic effects if linked to drug molecules. It has great significance of the new MRI contrast agent made of Fe 3 O 4 /TiO 2  composite nano-particles in improving MRI test sensitivity, decreasing cost of medical test and therapy, and safeguarding people&#39;s life and health. 
       SUMMARY OF THE INVENTION TECHNICAL PROBLEM 
       [0006]    The technique issue involved in the present invention is how to apply Fe 3 O 4 /TiO 2  composite nano-particles of small particle size with high solubility and biocompatibility to preparation of MRI contrast agents. 
       THE TECHNICAL SOLUTION  
       [0007]    The invention provides a method of preparing Fe 3 O 4 /TiO 2  composite nano-particles to solve the issue above, comprising the following steps: trivalent iron compounds and bivalent iron compounds are dissolved into a reducing acid solution; and the solution is added with a tetravalent titanium salt solution to obtain the Fe 3 O 4 /TiO 2  composite nano-particle sol. 
         [0008]    Optionally, the method further comprises the step that surfactants are added into the Fe 3 O 4 /TiO 2  composite nano-particle sol to regulate the nano-particle size, preventing nano-particles from aggregation and over growth. The preferred surfactant is cetyl trimethyl ammonium bromide or sodium dodecyl sulfate. 
         [0009]    Optionally, the method further comprises the step that the obtained Fe 3 O 4 /TiO 2  composite nano-particle sol is subject to aging treatment in water bath at 20° C.-99 ° C. for over 20 hours to obtain nano-particles of even particle size which are consistent in the need of MRI contrast agents. 
         [0010]    Optionally, the mole ratio of trivalent iron compound to bivalent iron compound is from 2:1 to 1:1, and the mole ratio of bivalent iron compound to reducing acid is from 1:12 to 1:1. Through creative work, the inventors found the materials of these ratios can obtain small Fe 3 O 4 /TiO 2  composite nano-particles of even size. 
         [0011]    Optionally, the reaction is at 0° C.-100° C. Optionally, the concentration of the tetravalent titanium salt solution is from 0.01 mol/L to 5 mol/L. The inventors found the tetravalent titanium salt solution of this concentration at this temperature can prepare Fe 3 O 4 /TiO 2  composite nano-particles of a controllable particle size. 
         [0012]    In addition, another aspect of the invention relates to the Fe 3 O 4 /TiO 2  composite nano-particles prepared by the method. 
         [0013]    Optionally, TiO 2  accounts for 10%-90% of nano-particles in weight. The inventors found that TiO 2  of this weight percent can ensure the Fe 3 O 4 /TiO 2  composite nano-particles have better magnetism and MRI signals, and maintain the biocompatibility of TiO 2  components. 
         [0014]    Another aspect of the invention is that the Fe 3 O 4 /TiO 2  composite nano-particles are applied to MRI contrast agents. 
       Beneficial Results 
       [0015]    In the present invention, the method of preparing Fe 3 O 4 /TiO 2  composite nano-particles has the advantages of simple operation, low cost, evenly distributed and controllable particle size, non-toxicity, good solubility and biocompatibility without the need for N 2  protection during the reaction process. 
         [0016]    The Fe 3 O 4 /TiO 2  composite nano-particles prepared by the method in the invention is a composite nano material having both super paramagnetism and photocatalytic activity, which has wide application prospects in medical imaging diagnosis and medical treatment. Super paramagnetic Fe 3 O 4  components can have medical imaging function and separate the photo-generated holes on the TiO 2  surface from ions, which prolongs the bonding time of holes and ions, improves the photocatalytic activity and enhance the therapeutic effects of TiO 2  components. Moreover, TiO 2  components can protect Fe 3 O 4  components from oxidation. The MRI contrast agent made of Fe 3 O 4 /TiO 2  composite nano-particles can have T 1 , T 2  and/or T 2 * weighted signals and realize both medical diagnosis and therapeutic effects if TiO 2  components with good biocompatibility are linked to drug molecules by covalent bonds to form nano copolymers. 
     
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
         [0017]      FIG. 1  is the TEM diagram of Fe 3 O 4 /TiO 2  composite nano-particles prepared by an embodiment of the invention. 
           [0018]      FIG. 2  is the HRTEM diagram of Fe 3 O 4 /TiO 2  composite nano-particles shown in  FIG. 1 . 
           [0019]      FIG. 3  is the XRD diagram of Fe 3 O 4 /TiO 2  composite nano-particles prepared by an embodiment of the invention. 
           [0020]      FIG. 4  is the magnetization curve of Fe 3 O 4 /TiO 2  composite nano-particles prepared by an embodiment of the invention. 
           [0021]      FIG. 5  is a T 1  and T 2  weighted signal chart in MRI test of Fe 3 O 4 /TiO 2  composite nano-particles prepared by an embodiment of the invention. 
       
    
    
     DESCRIPTION OF THE PREFERRED EMBODIMENT 
       [0022]    The Fe 3 O 4 /TiO 2  composite nano-particles related to the invention are prepared by the following steps: 
         [0023]    1. A certain amount of reducing acid is weighed and dissolved in water, and then stirred adequately to obtain the reducing acid solution with the concentration of 0.01 mol/L to 1 mol/L; 
         [0024]    2. Trivalent ferric salt and bivalent ferric salt with the ratio of 2:1 to 1:1, among which the ratio of Fe 2+  and reducing acid is 1:12 to 1:1, are added into the reducing acid solution, and then stirred adequately at 0° C.-99° C., preferably 20° C.-30° C. for less than an hour; 
         [0025]    3. The ferric salt solution is put into ice bath and added with the tetravalent titanium salt solution of 0.01 mol/L-5 mol/L molar concentration in a dropwise manner until the TiO 2  component accounts for 10%-90% of the total TiO 2  and Fe 3 O 4  components, and then stirred adequately for over one hour; 
         [0026]    5. The solution is added with appropriate surfactants after reaction and continues to be stirred for over 30 min; 
         [0027]    6. The prepared solution is subject to aging treatment in water bath at 20° C. above for more than 20 hours to obtain the Fe 3 O 4 /TiO 2  composite nano-particle sol; 
         [0028]    7. The obtained Fe 3 O 4 /TiO 2  composite nano-particle sol is packed into reagent bottles and put into a refrigerator at 4° C. for MRI contrast agent; or the sol is dialyzed, frozen and dried to obtain a powder product for MRI contrast agents. 
         [0029]    The surfactant is cetyl trimethyl ammonium bromide (CTAB) or sodium dodecyl sulfate (SDS), which can effectively improve nano-particles aggregation phenomenon. 
         [0030]    The Fe 3 O 4 /TiO 2  composite nano-particles obtained by above method can be evenly dispersed in water and water solution to form transparent lyosol, which proves that the sol has a good dispersibility. Moreover, the sol can be kept at 4° C. for more than 1 year, which shows the Fe 3 O 4 /TiO 2  composite nano-particle sol have good solubility and stability. 
         [0031]    In addition, the Fe 3 O 4 /TiO 2  composite nano-particles also have very good biocompatibility as Fe 3 O 4  and TiO 2  have very good biocompatibility. 
         [0032]    The above implementation method is described in detail with the following embodiments. 
       EMBODIMENT 1 
       [0033]    (1) Citric acid of 3 mmol was taken to dissolve in deionized water of 350 mL, and vigorously stirred for full dissolution of citric acid to obtain the citric acid solution; 
         [0034]    (2) FeCl 3 .6H 2 O of 2 mmol and FeCl 2 .4H 2 O of 1 mmol were taken to dissolve in the citric acid solution, and adequately stirred; 
         [0035]    (3) The reaction vessel was placed in the ice bath and stirred for 30 min. 
         [0036]    (4) The reaction vessel was added with 0.1 mol/L TiCl 4  solution of 10 mL in a dropwise manner and continued to be stirred; 
         [0037]    (5) After 5 hours, the product was put into a water bath boil at 65° C. and subject to aging treatment for 22 hours; 
         [0038]    (6) The product was dialyzed, frozen and dried to obtain Fe 3 O 4 /TiO 2  composite nano-particle powder. 
       EMBODIMENT 2 
       [0039]    (1) Citric acid of 6 mmol was taken to dissolve in deionized water of 350 mL, and vigorously stirred for full dissolution of citric acid to obtain the citric acid solution; 
         [0040]    (2) FeCl 3 .6H 2 O of 4 mmol and FeCl 2 .4H 2 O of 2 mmol were taken to dissolve in the citric acid solution, and adequately stirred; 
         [0041]    (3) The reaction vessel was placed in the ice bath and stirred for 30 min. 
         [0042]    (4) The reaction vessel was added with 0.6 mol/L TiCl 4  solution of 1 mL in a dropwise manner and continued to be stirred; 
         [0043]    (5) After 5 hours, the product was added with 0.8 mmol/L CTAB of 50 mL and stirred for 30 min; 
         [0044]    (6) The product was put into a water bath boil at 65° C. and subject to aging treatment for 20 hours. 
         [0045]    (7) The product was dialyzed, frozen and dried to obtain Fe 3 O 4 /TiO 2  composite nano-particle powder. 
       EMBODIMENT 3 
       [0046]    (1) Citric acid of 6 mmol was taken to dissolve in deionized water of 350 mL, and vigorously stirred for full dissolution of citric acid to obtain the citric acid solution; 
         [0047]    (2) FeCl 3 .6H 2 O of 2 mmol and FeCl 2 .4H 2 O of 2 mmol were respectively taken to dissolve in the said citric acid solution, and adequately stirred; 
         [0048]    (3) The reaction vessel was placed in the ice bath and stirred for 30 min. 
         [0049]    (4) The reaction vessel was added with 0.1 mol/L TiCl 4  solution of 20 mL in a dropwise manner and continued to be stirred; 
         [0050]    (5) After 5 hours, the product was added with 0.8 mmol/L SDS of 50 mL and stirred for 30 min; 
         [0051]    (6) The product was put into a water bath boil at 65° C. and subject to aging treatment for 20 hours. 
         [0052]    (7) The product was dialyzed, frozen and dried to obtain Fe 3 O 4 /TiO 2  composite nano-particle powder. 
         [0053]      FIG. 1  and  FIG. 2  are TEM and HRTEM diagrams of Fe 3 O 4 /TiO 2  composite nano-particles prepared by said Embodiment 1. The Fe 3 O 4 /TiO 2  composite nano-particles have good dispersibility and even particle size (average size: about 5 nm for a single particle) as shown in  FIG. 1  and  FIG. 2 . 
         [0054]      FIG. 3  is the XRD diagram of Fe 3 O 4 /TiO 2  composite nano-particles prepared by said Embodiment 1 (Cu Kα target, λ=0.15418 nm). Tetragonal TiO 2  and cubic Fe 3 O 4  diffraction peaks as shown in  FIG. 3  indicate that Fe 3 O 4 /TiO 2  composite nano-particles have the crystal structure of Fe 3 O 4  and TiO 2 . 
         [0055]      FIG. 4  is the magnetization curve of the Fe 3 O 4 /TiO 2  composite nano-particles prepared by said Embodiment 1, which was obtained with American Quantum Design comprehensive physical property test (Model-9, test conditions: VSM (vibrating sample magnetometer) test, temperature: 300 K).  FIG. 4  shows the Fe 3 O 4 /TiO 2  composite nano-particles have the saturation intensity of about 16.95 emu/g, the coercive force and remanence of 0, indicating that Fe 3 O 4 /TiO 2  composite nano-particles have super paramagnetism. Therefore, Fe 3 O 4 /TiO 2  composite nano-particles can be effectively applied in MRI contrast agents. 
         [0056]      FIG. 5  shows T 1  and T 2  weighted signal diagram in the MRI test of Fe 3 O 4 /TiO 2  composite nano-particles prepared by Embodiment 3. MIR test conditions are: TR=300 ms, TE=6 ms, T 2 :TR=4000 ms, TE=120 ms. Sample a, b and c are nano Fe 3 O 4 ; sample d is the Fe 3 O 4 /TiO 2  composite nano-particle prepared by Embodiment 3; and e is the water solution for control. 
         [0057]      FIG. 5  shows that all nano Fe 3 O 4  samples have T 2  weighted signals, but only the nano Fe 3 O 4  sample b has relatively weak weighted signals T 1 . The Fe 3 O 4 /TiO 2  composite nano-particle sample prepared by Embodiment 3 has both strong T 1  and T 2  weighted signals. 
         [0058]    The invention is disclosed as mentioned above, but it does not limit the claims. Any technician in this field can change and revise it without departing from the scope and essence of the invention. Therefore, the invention protects these defined in the Claims.